Navigation Links
Advancing understanding of treatment through clinical trials
Date:11/3/2012

Three late-breaking studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on drugs being tested in patients with diabetes or kidney disease.

Hans-Henrik Parving, MD (University of Copenhagen, in Denmark) and his colleagues investigated whether the drug aliskiren might improve the prognosis of patients with type 2 diabetes who are at high risk for developing heart and kidney problems. The randomized double-blind ALTITUDE trial included 8561 individuals who received aliskiren (300 mg once daily) or placebo on top of a drug that blocks the renin-angiotensin-aldosterone system (RAAS), a complex hormone system that regulates blood pressure and fluid balance. (Drugs that target the RAAS have limited effectiveness in part due to feedback responses, such as compensatory increases in an enzyme called renin. Aliskiren is a direct renin inhibitor and may help overcome these shortcomings because it suppresses the reactive rise in renin activity stimulated by other RAAS blockers.) After an average follow-up of 32.9 months:

  • 17.9% of patients receiving aliskiren and 16.8% of those receiving placebo experienced a heart attack or stroke, developed kidney disease, or died of cardiovascular disease.
  • Stroke occurred in 3.4% of patients taking aliskiren, compared with 2.7% of patients taking placebo.
  • Patients taking aliskiren experienced significantly increased blood potassium levels and hypotension.

"The trial does not support administration of aliskiren on top of standard therapy with RAAS blockade in type 2 diabetic patients at high risk for cardiovascular and renal events, and may even be harmful," the authors concluded.

Another team led by Vicente Torres, MD, PhD (Mayo Clinic) tested the potential of a vasopressin V2 receptor antagonist (tolvaptan) to inhibit cyst growth and slow kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD). This condition causes kidney cysts often associated with pain, hypertension, and kidney failure. The phase 3, multi-center, double-blind, placebo-controlled, 3-year trial included 1445 ADPKD patients who were randomized 2:1 to split dose tolvaptan (45/15, 60/30 or 90/30 mg daily as tolerated) or placebo.

  • Total kidney volume increase over 3 years was halved in patients treated with tolvaptan compared to placebo (2.80%/year versus 5.51%/year).
  • Patients taking tolvaptan were 61% less likely to experience a certain level of worsening kidney function and 36% less likely to experience kidney pain requiring treatment.
  • Tolvaptan slowed the rate of kidney function decline compared with placebo.

"Tolvaptan demonstrated clinically meaningful disease-specific benefits for ADPKD patients which may be clinically meaningful," said Dr. Torres. While the trial findings are encouraging, tolvaptan has not yet been approved for this indication.

A third trial, called EVOLVE, was designed to test the hypothesis that treatment with cinacalcet compared with placebo reduces the risk of premature death or non-fatal heart-related events among dialysis patients with secondary hyperparathyroidism. (Secondary hyperparathyroidism, when the parathyroid gland produces excess amounts of parathyroid hormone, arises in most patients with chronic kidney disease as their disease progresses. It can lead to a number of complications, including cardiovascular problems.) Results from analyses using multivariable adjustment and censoring data 6 months after patients stopped taking the drug will be presented, along with safety data, by Glenn Chertow, MD (Stanford University School of Medicine).


'/>"/>

Contact: Adrienne Lea
alea@asn-online.org
202-503-6560
American Society of Nephrology
Source:Eurekalert

Related medicine news :

1. Advancing the treatment of trauma
2. Researchers closer to understanding actions of cells involved in atherosclerosis
3. Studies seek better understanding and treatment of depression
4. Wayne State develops better understanding of memory retrieval between children and adults
5. Understanding flirtation in negotiation, shooter bias, love during marriage, and more
6. Discovery improves understanding of early onset inflammatory disease
7. Cedars-Sinai researchers, with stem cells, advance understanding of spinal muscular atrophy
8. Understanding the links between inflammation and chronic disease
9. Understanding and promoting mental health - Insights from psychological science
10. Researchers gain better understanding of mechanism behind tau spreading in the brain
11. Mayo Clinic identifies promising treatment for inherited form of kidney disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, pocket knife, ... Cradle to Cradle Product Design Challenge , the Cradle to Cradle Products ... six circular design challenges scheduled to run through early 2018. The challenges are presented ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Neil H. ... financial planning assistance to communities throughout the region, is launching a charity drive to ... disease is by far the deadliest killer in America, and is responsible for 1 ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SC&H Group, ... firm as a Principal in its IT Advisory Services practice . Rossi is ... months as market demand for strategic IT guidance grows, and the practice continues to ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... to visualize, detect, and eliminate cyber threats in real-time, today announced a strategic ... provider, headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... families from two offices in Tyler, has announced the latest beneficiary of their ... Wish Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ill ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 According to a new market research report "Neural Network ... Software), Vertical, and Region - Global Forecast to 2021" published by MarketsandMarkets, the ... by 2021, at a Compound Annual Growth Rate (CAGR) of 33.2%. ... ... MarketsandMarkets Logo ...
(Date:1/17/2017)... and KANSAS CITY, Mo. ... Hospitals Neonatal Consortium (CHNC) has selected Velos and ... visionary data management and multicenter initiatives. ... comprised of 32 Neonatal Intensive Care Units at ... . The consortium provides a benchmark of ...
(Date:1/17/2017)... --  Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today ... and pharmaceutical development at Tocagen, will present at Phacilitate Cell ... in Miami . Details of ... ... viruses - what to do when and why Date and Time: ...
Breaking Medicine Technology: